Liver Diseases
Breath biomarker discovery with Breath Biopsy® could enable non-invasive early detection and disease progression monitoring for NAFLD, NASH and other liver diseases.
Liver Disease
Biomarkers for Liver Disease
Today as many as 3 in 10 adults and 1 in 10 children are affected by liver disease in some countries.1 Despite increasing incidence detecting liver disease, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and more advanced cirrhosis, is challenging. These conditions all share common clinical presentations, making accurate diagnosis and effective treatment a critical challenge.
Human breath contains over 1000 different volatile organic compounds (VOCs) which can originate from endogenous metabolism or exogenous sources such as diet, the environment or the microbiome. Collecting and analyzing these compounds can be a rich source of information relevant to health and disease. By developing Breath Biopsy®, Owlstone Medical have become the world-leaders in robust and reliable, non-invasive breath collection for biomarker discovery research.
1.Definition & Facts of NAFLD & NASH: https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts
Biomarkers of liver disease originate directly within the liver and are then transferred into breath via the bloodstream. As such breath tests have the potential to detect systemic markers of liver diseases. Breath Biopsy uses the ReCIVA® Breath Sampler for non-invasive breath sample collection and provides robust biomarker discovery pipelines using GC-MS analysis provided through Breath Biopsy Services.
Find out more about using Breath Biopsy for Liver Diseases:
Contact Our Team for More Information About Breath Biopsy Products and Services
Get in Touch
Recommended Reading
Other recommended reading:
- PUBLICATION: Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound—Toward Improved Detection of Liver Impairment
- POSTER: Breath Biopsy to Discover Novel Exogenous Volatile Organic Compound (EVOC®) Biomarkers for Chronic Liver Disease
- PUBLICATION: Volatile Biomarkers in Breath Associated With Liver Cirrhosis — Comparisons of Pre- and Post-liver Transplant Breath Samples
- PAPER: Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes
- BLOG: Avoiding background signals – How the CASPER™ Portable Air Supply enhances Breath Biopsy results
- BLOG: Breath analysis of liver diseases – The Story So Far
- DOWNLOAD: Breath Biopsy: The Complete Guide – Over 100 pages packed with everything you need to know about breath research, and the applications and technologies of Breath Biopsy
- BLOG: Why are CYP enzymes a key focus for liver disease research?
- WATCH: Breath Biopsy Conference 2020 session: Breath Biomarkers for Liver Disease
- BLOG: The benefits of breath sampling – Seven reasons to collect and analyze breath samples for your research
- INTERVIEW: Meet Rob Smith, Senior Applications Chemist at Owlstone Medical, working with the GC-MS technology to link levels of breath limonene with cirrhosis
- PUBLICATION: Non-Invasive Distinction of Non-Alcoholic Fatty Liver Disease using Urinary Volatile Organic Compound Analysis: Early Results
- BLOG: Tips for study design – Get the most out of Breath Biopsy with careful planning
- CASE STUDY: A pilot study using FAIMS analysis of exhaled VOCs to detect hepatic encephalopathy
